Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Elevai Labs, Inc. Common Stock (ELAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: ELAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.94M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.95 - 839.86 | Updated Date 06/29/2025 |
52 Weeks Range 1.95 - 839.86 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.44 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.92% | Return on Equity (TTM) -95.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3351530 | Price to Sales(TTM) 2.34 |
Enterprise Value -3351530 | Price to Sales(TTM) 2.34 | ||
Enterprise Value to Revenue 2.59 | Enterprise Value to EBITDA - | Shares Outstanding 1375380 | Shares Floating 1259303 |
Shares Outstanding 1375380 | Shares Floating 1259303 | ||
Percent Insiders 0.49 | Percent Institutions 2.99 |
Upturn AI SWOT
Elevai Labs, Inc. Common Stock
Company Overview
History and Background
Elevai Labs, Inc. focuses on developing and marketing topical cosmeceuticals using exosomes. Founded in 2020, the company aims to address aging skin and promote skin rejuvenation through science-backed products. They went public via IPO on February 8, 2024.
Core Business Areas
- Topical Skincare: Development and sale of cosmeceutical products, including serums and creams, designed to improve skin appearance and health.
Leadership and Structure
Dr. Jordan Plews is the CEO. The company has a board of directors and operates with a small team focusing on product development, marketing, and sales. It outsources manufacturing.
Top Products and Market Share
Key Offerings
- Elevai E-Series Professional: A line of topical exosomes designed to promote skin rejuvenation. Market share is currently small but emerging within the overall cosmeceutical market. Competitors include AnteAGE, Benir Beauty, and other exosome-based skincare companies. Precise market share data is not readily available for emerging products.
- enfinity: A product designed to help the skin work more efficiently for longer periods. Market share is currently small but emerging within the overall cosmeceutical market. Competitors include AnteAGE, Benir Beauty, and other exosome-based skincare companies. Precise market share data is not readily available for emerging products.
Market Dynamics
Industry Overview
The cosmeceutical industry is growing rapidly, driven by consumer demand for effective anti-aging and skin rejuvenation products. Exosome-based skincare is a newer segment experiencing significant growth.
Positioning
Elevai Labs is positioned as an innovative player in the cosmeceutical market, focusing on exosome technology. Their competitive advantage lies in proprietary formulations and scientific backing.
Total Addressable Market (TAM)
The global cosmeceuticals market is estimated to reach hundreds of billions of dollars. Elevai Labs, Inc. is targeting a small but growing segment of this TAM with its exosome-based products. Precise TAM data on exosome skincare alone is still developing, but growth projections are high.
Upturn SWOT Analysis
Strengths
- Innovative exosome technology
- Science-backed formulations
- Strong leadership with industry expertise
- Early mover advantage in exosome skincare
Weaknesses
- Small market share
- Limited brand recognition
- Dependence on outsourced manufacturing
- Limited financial resources as a newly public company
Opportunities
- Expanding distribution channels
- Developing new product lines
- Increasing brand awareness through marketing
- Partnering with aesthetic professionals
- Capitalizing on the growing cosmeceutical market
Threats
- Competition from established cosmeceutical brands
- Regulatory scrutiny of exosome products
- Potential for technological advancements to render products obsolete
- Economic downturn impacting consumer spending
Competitors and Market Share
Key Competitors
- ALVR
- AGN
- SNY
Competitive Landscape
Elevai Labs faces strong competition from established cosmeceutical companies with greater brand recognition and financial resources. Their advantage lies in their innovative exosome technology, but they need to execute effectively to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Limited historical data due to recent IPO.
Future Projections: Analysts expect high revenue growth rates based on the potential of exosome skincare and expansion plans, but estimates are speculative at this stage.
Recent Initiatives: Recent initiatives include expanding distribution channels, increasing marketing efforts, and developing new products.
Summary
Elevai Labs is a newly public, innovative company in the cosmeceutical sector with a focus on exosome-based skincare. Its strengths lie in its unique technology and experienced leadership, but it faces challenges from established competitors and the need to scale rapidly. The company's success will depend on effective marketing, product development, and strategic partnerships. Cash flow and regulatory hurdles related to exosomes will need to be monitored.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Elevai Labs, Inc. SEC Filings
- Market Research Reports on the Cosmeceutical Industry
- Financial News Articles
- Company Website
Disclaimers:
This analysis is based on available information and analyst estimates, which are subject to change. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated, particularly for emerging product categories. Analysis based on information available as of October 26, 2024.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elevai Labs, Inc. Common Stock
Exchange NASDAQ | Headquaters Newport Beach, CA, United States | ||
IPO Launch date 2023-11-21 | CEO, CFO, Secretary & Director Mr. Graydon Bensler C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://pmgcholdings.com |
Full time employees 2 | Website https://pmgcholdings.com | ||
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.